Journal of Surgery Concepts & Practice ›› 2018, Vol. 23 ›› Issue (02): 169-172.doi: 10.16139/j.1007-9610.2018.02.018
• Review • Previous Articles Next Articles
Received:2018-02-05
Online:2018-03-25
Published:2020-07-25
CLC Number:
| [1] Lim H, Devesa SS, Sosa JA, et al.Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA,2017,317(13):1338-1348. [2] Wendler J, Kroiss M, Gast K, et al.Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany[J]. Eur J Endocrinol,2016,175(6):521-529. [3] Segerhammar I, Larsson C, Nilsson IL, et al.Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution[J]. J Surg Oncol,2012, 106(8):981-986. [4] Ranganath R, Shah MA, Shah AR.Anaplastic thyroid cancer[J]. Curr Opin Endocrinol Diabetes Obes,2015,22(5):387-391. [5] Smallridge RC, Ain KB, Asa SL, et al.American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer[J]. Thyroid,2012,22(11):1104-1139. [6] Landa I, Ibrahimpasic T, Boucai L, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J]. J Clin Invest,2016,26(3):1052-1066. [7] Smallridge RC, Marlow LA, Copland JA.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies[J]. Endocr Relat Cancer,2009,16(1):17-44. [8] Jeon MJ, Chun SM, Kim D, et al.Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAF(V600E) mutation-prevalent area[J]. Thyroid,2016,26(5):683-690. [9] Liu Z, Hou P, Ji M, et al.Highly prevalent genetic altera-tions in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers[J]. J Clin Endocrinol Metab,2008,93(8):3106-3116. [10] Lee J, Hwang JA, Lee EK.Recent progress of genome study for anaplastic thyroid cancer[J]. Genomics Inform,2013,11(2):68-75. [11] Ensinger C, Spizzo G, Moser P, et al.Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas[J]. Ann N Y Acad Sci,2004,1030:69-77. [12] Arora A, Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J]. J Pharmacol Exp Ther,2005,315(3):971-979. [13] Kim S, Yazici YD, Calzada G, et al.Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Mol Cancer Ther,2007,6(6):1785-1792. [14] Brose MS, Nutting CM, Jarzab B, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet,2014,384(9940):319-328. [15] Savvides P, Nagaiah G, Lavertu P, et al.Phase Ⅱ trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J]. Thyroid,2013,23(5):600-604. [16] Ha HT, Lee JS, Urba S, et al.A phase Ⅱ study of imatinib in patients with advanced anaplastic thyroid cancer[J]. Thyroid,2010,20(9):975-980. [17] Xu CF, Xue Z, Bing N, et al.Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer[J]. Ann Oncol,2012,23(9):2470-2471. [18] Bible KC, Suman VJ, Menefee ME, et al.A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer[J]. J Clin Endocrinol Metab,2012,97(9):3179-3184. [19] McLarnon A. Thyroid cancer: Pazopanib alone is not effective against anaplastic thyroid cancer[J]. Nat Rev Endocrinol,2012,8(10):565. [20] Isham CR, Bossou AR, Negron V, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer[J]. Sci Transl Med,2013,5(166):166ra3. [21] Miyake H, Miyazaki A, Imai S, et al.Early tumor shrinka-ge under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan[J]. Target Oncol,2016,11(2):175-182. [22] Di Desidero T, Fioravanti A, Orlandi P, et al.Antiproli-ferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1[J]. J Clin Endocrinol Metab,2013,98(9):E1465-E1473. [23] Bikas A, Kundra P, Desale S, et al.Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer[J]. Eur J Endocrinol,2016,174(3):373-380. [24] Glen H, Mason S, Patel H, et al.E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion[J]. BMC Cancer,2011,11:309. [25] Schlumberger M, Tahara M, Wirth LJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med,2015,372(7):621-630. [26] Takahashi S, Tahara M, Kiyota N, et al. Phase Ⅱ study of lenvatinib(LEN), a multi-targeted tyrosine kinase inhibitor, in patients(PTS) with all histologic subtypes of advanced thyroid cancer[J]. Ann Oncol,2014,25(suppl 4): iv343-iv344. [27] Tahara M, Kiyota N, Yamazaki T, et al.Lenvatinib for anaplastic thyroid Cancer[J]. Front Oncol,2017,7:25. [28] Lim SM, Chang H, Yoon MJ, et al.A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes[J]. Ann Oncol,2013,24(12):3089-3094. [29] Wagle N, Grabiner BC, van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer[J]. N Engl J Med,2014,371(15):1426-1433. [30] Bollag G, Hirth P, Tsai J, et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma[J]. Nature,2010,467(7315):596-599. [31] Rosove MH, Peddi PF, Glaspy JA.BRAF V600E inhibition in anaplastic thyroid cancer[J]. N Engl J Med,2013, 368(7):684-685. [32] Hyman DM, Puzanov I, Subbiah V, et al.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. N Engl J Med,2015,373(8):726-736. [33] Pennell NA, Daniels GH, Haddad RI, et al.A phase Ⅱ study of gefitinib in patients with advanced thyroid cancer[J]. Thyroid,2008,18(3):317-323. [34] Tozer GM, Kanthou C, Baguley BC.Disrupting tumour blood vessels[J]. Nat Rev Cancer,2005,5(6):423-435. [35] Dark GG, Hill SA, Prise VE, et al.Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature[J]. Cancer Res,1997,57(10):1829-1834. [36] Sosa JA, Elisei R, Jarzab B, et al.Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma[J]. Thyroid,2014,24(2):232-240. [37] Mooney CJ, Nagaiah G, Fu P, et al.A phase Ⅱ trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome[J]. Thyroid,2009,19(3):233-240. |
| [1] | YAN Haibo, XIA Zhongping, CHEN Shan, JIANG Lin, HAN Chun. Risk factors for Delphian lymph node metastasis in papillary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 453-457. |
| [2] | LI Rui, LIU Zhuoran, YAN Jiqi. Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 271-275. |
| [3] | CHEN Chengkun, GUO Bomin, DENG Xianzhao, WU Bo, FAN Youben. Diagnosis and treatment of medullary thyroid carcinoma-an update [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 276-280. |
| [4] | WU Chunxiao, GU Kai, PANG Yi, BAO Pingping, WANG Chunfang, SHI Liang, XIANG Yongmei, GONG Yangming, DOU Jianming, WU Mengyin, FU Chen, SHI Yan. Thyroid cancer incidence and mortality in Shanghai China 2016 and trends from 2002 to 2016 [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 58-65. |
| [5] | LIU Rongyao, LI Xiangcui, WANG Lina, CHEN Haizhen. Analysis of risk factors for cervical lymph node metastasis in papillary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 76-79. |
| [6] | . [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 564-567. |
| [7] | FAN Jinfang, SHEN Yi, ZHAN Weiwei, TAO Lingling, LI Weiwei, KUANG Lijun, ZHOU Wei. Clinicopathological analysis of papillary thyroid microcarcinoma in isthmus [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 528-531. |
| [8] | ZHANG Gang, ZHANG Zhe, ZHANG Shu, LI Zhirong, TIAN Wuguo, HUANG Qi, WANG Lingli, XU Yan. Association between RET genotype and disease phenotype in patients with hereditary medullary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 522-527. |
| [9] | SUN Hanxing, SHEN Xiaohui, GAO Haoji, LIU Zhuoran, CHEN Xi, QIU Weihua, YAN Jiqi. Preoperative evaluation and preparation of Graves′ disease: a report of 126 cases [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 517-521. |
| [10] | YAN Shouyi, CHEN Hongbin, ZHANG Liyong, WANG Bo, CAI Shaojun, LIN Siying, ZHAO Wenxin. Retrospective study on Bethesda Ⅴ thyroid nodule in diagnosis of papillary thyroid carcinoma: retrospective study [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 512-516. |
| [11] | . [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 504-509. |
| [12] | . [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 497-499. |
| [13] | . [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 493-496. |
| [14] | . [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 486-492. |
| [15] | . [J]. Journal of Surgery Concepts & Practice, 2021, 26(6): 482-485. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
